Johnson & Johnson
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JNJ research report →
Companywww.jnj.com
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand.
- CEO
- Joaquin Duato
- IPO
- 1943
- Employees
- 138,100
- HQ
- New Brunswick, NJ, US
Price Chart
Valuation
- Market Cap
- $552.02B
- P/E
- 26.65
- P/S
- 5.73
- P/B
- 6.91
- EV/EBITDA
- 17.33
- Div Yield
- 2.27%
Profitability
- Gross Margin
- 69.12%
- Op Margin
- 26.87%
- Net Margin
- 21.83%
- ROE
- 26.26%
- ROIC
- 13.60%
Growth & Income
- Revenue
- $94.19B · 6.05%
- Net Income
- $26.80B · 90.56%
- EPS
- $11.03 · 88.87%
- Op Income
- $25.60B
- FCF YoY
- -0.73%
Performance & Tape
- 52W High
- $251.71
- 52W Low
- $149.04
- 50D MA
- $234.03
- 200D MA
- $209.83
- Beta
- 0.26
- Avg Volume
- 7.89M
Get TickerSpark's AI analysis on JNJ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | REED JOHN C | other | 25,255 |
| May 1, 26 | REED JOHN C | other | 11,002 |
| May 1, 26 | REED JOHN C | other | 25,255 |
| Apr 23, 26 | Woods Eugene A. | other | 975 |
| Apr 23, 26 | West Nadja | other | 975 |
| Apr 23, 26 | WEINBERGER MARK A | other | 975 |
| Apr 23, 26 | Pinto Daniel E | other | 1,712 |
| Apr 23, 26 | MORIKIS JOHN G | other | 1,540 |
| Apr 23, 26 | McClellan Mark B. | other | 975 |
| Apr 23, 26 | Joly Hubert | other | 975 |
Our JNJ Coverage
We haven't published any research on JNJ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate JNJ Report →